Abstract: This disclosure provides modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) having core structure (I), pharmaceutical compositions containing at least one such modulator, methods of treatment of CFTR mediated diseases, including cystic fibrosis, using such modulators and pharmaceutical compositions, combination pharmaceutical compositions and combination therapies employing those modulators, and processes and intermediates for making such modulators.

Abstract: An optical system (31) for analysing biological processes comprising: a biological process vessel (33) comprising a chamber and an optical interface element (34) for optically coupling the chamber to an optical emitter, a wavelength discrimination component, and an optical detector when a biological process fluid in the chamber is being analysed, the optical interface element being configured to couple light in the mid-infrared range; an optical emitter (351) configured to emit light in the mid-infrared range; an optical detector (353) configured to detect light in the mid-infrared range; a wavelength discrimination component (352); an alignment component (42) for aligning the optical emitter, optical detector, and wavelength discrimination component with the optical interface element; and a processor (354) configured to: receive outputs from the optical detector; and process the received outputs from the optical detector to provide an indication of the constituents of a biological process fluid in the chambe

Abstract: The present disclosure provides methods and compositions for controlling asphaltenes in a subterranean formation. The compositions may include a halloysite nanotube. The nanotube has a lumen and a polymer, along with a charged surfactant, may be disposed in the lumen. A wax may be disposed on the nanotube. The wax may be disposed at either or both ends of the nanotube, thereby temporarily preventing the polymer and charged surfactant from leaving the lumen.

Abstract: Methods for assessing the stability of asphaltene by measuring the field strength of the production fluid of asphaltene containing hydrocarbon stream have been developed. These methods can be used for monitoring of asphaltene control chemical application effectiveness during crude oil production and refinement.

Abstract: A method for range detection is described. The method includes segmenting an image into one or more segmentation blobs captured by a monocular camera of an ego vehicle. The method includes focusing on pixels forming a selected segmentation blob of the one or more segment blobs. The method also includes determining a distance to the selected segmentation blob according to a focus function value of the monocular camera of the ego vehicle.

Abstract: This disclosure provides modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) having core structure (I), pharmaceutical compositions containing at least one such modulator, methods of treatment of CFTR mediated diseases, including cystic fibrosis, using such modulators and pharmaceutical compositions, combination pharmaceutical compositions and combination therapies, and processes and intermediates for making such modulators.

Abstract: Compounds of Formula (I): pharmaceutically acceptable salts thereof, deuterated derivatives of any of the foregoing, and metabolites of any of the foregoing are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed.

Abstract: This disclosure provides modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) having core structure (I), pharmaceutical compositions containing at least one such modulator, methods of treatment of cystic fibrosis using such modulators and pharmaceutical compositions, combination pharmaceutical compositions and combination therapies, and processes and intermediates for making such modulators.

Abstract: This disclosure provides modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR)having the core structure: pharmaceutical compositions containing at least one such modulator, methods of treating CFTR mediated diseases, including cystic fibrosis, using such modulators and pharmaceutical compositions, combination therapies, and processes and intermediates for making such modulators.

Abstract: This disclosure provides modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) having the core structure: pharmaceutical compositions containing at least one such modulator, methods of treatment of CFTR mediated diseases, including cystic fibrosis, using such modulators and pharmaceutical compositions, combination pharmaceutical compositions and combination therapies, and processes and intermediates for making such modulators.

Abstract: This disclosure provides modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR), having the core structure: pharmaceutical compositions containing at least one such modulator, methods of treatment of mediated diseases, such as cystic fibrosis, using such modulators and pharmaceutical compositions, combination pharmaceutical compositions and therapies comprising such modulators, and processes and intermediates for making such modulators.

Abstract: This disclosure provides modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) having the core structure: pharmaceutical compositions containing at least one such modulator, methods of treatment of cystic fibrosis using such modulators and pharmaceutical compositions, combination therapies, and processes and intermediates for making such modulators.

Abstract: Compounds of Formula (I): pharmaceutically acceptable salts thereof, deuterated derivatives of any of the foregoing, and metabolites of any of the foregoing are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed. Also disclosed are solid state forms of Compound 1 and salts and solvates thereof.

Abstract: This disclosure provides modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR), pharmaceutical compositions containing at least one such modulator, methods of treatment of cystic fibrosis using such modulators and pharmaceutical compositions, and processes for making such modulators.

Abstract: The present disclosure pertains to a system for facilitating configuration modifications for a patient interface computer system based on risk of readmission of the patient. In some embodiments, the system obtains (i) patient demographics information associated with a patient, the patient previously having been admitted at a facility of a first type, (ii) disease information associated with the patient, and (iii) facility information associated with a facility of a second type, the facility information including one or more facility-specific factors associated with the facility of the second type. The system determines a risk of readmission to a facility of the first type for the patient based on the obtained patient demographics information, the disease information, and the facility information. The system causes a configuration of the patient interface computer system to be modified based on the determined risk of readmission.

Abstract: Compound (I), deuterated derivatives, and pharmaceutically acceptable salts of any of the foregoing are disclosed. Methods of treating cystic fibrosis using these compounds are also disclosed.

Abstract: The present disclosure provides methods and compositions for controlling asphaltenes in a subterranean formation. The compositions may include silica, a polymer, and optionally a charged surfactant. The compositions may also include a solvent or other additives. The methods may include injecting the compositions into subterranean formations and inhibiting asphaltene precipitation.

Abstract: This disclosure provides modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR), pharmaceutical compositions containing at least one such modulator, methods of treatment of cystic fibrosis using such modulators and pharmaceutical compositions, and processes for making such modulators.

Abstract: Compounds of Formula I: pharmaceutically acceptable salts thereof, deuterated derivatives of any of the foregoing, and metabolites of any of the foregoing are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed.

Abstract: Compounds of Formula (I): pharmaceutically acceptable salts thereof, deuterated derivatives of any of the foregoing, and metabolites of any of the foregoing are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed. Also disclosed are solid state forms of Compound 1 and salts and solvates thereof.